FAM
MREO

Formidable Asset Management’s Mereo BioPharma MREO Stock Holding History

Formidable Asset Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-331,914
Closed -$428K – 299
2023
Q3 		$428K Buy
+331,914
New +$440K 0.09% 186
2023
Q2 		– Sell
-331,914
Closed -$234K – 311
2023
Q1 		$234K Buy
331,914
+43,834
+15% +$39.4K 0.05% 253
2022
Q4 		$216K Buy
288,080
+6,262
+2% +$5.14K 0.05% 268
2022
Q3 		$242K Buy
281,818
+6,262
+2% +$7.66K 0.06% 246
2022
Q2 		$309K Buy
+275,556
New +$214K 0.07% 232

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Formidable Asset Management's MREO Position: Q4 2023 in Review

Formidable Asset Management sold out of Mereo BioPharma (MREO) in Q4 2023, closing a stake of 331,914 shares — an estimated $428K sold.

Formidable Asset Management first reported a position in MREO in Q2 2022 and held it in 5 quarters. The position peaked at $428K in Q3 2023. 64 funds tracked by Wall St. Rank hold MREO as of Q4 2023.

  • Formidable Asset Management reported no remaining Mereo BioPharma position as of Q4 2023 after selling out during the quarter.
  • Formidable Asset Management sold 331,914 Mereo BioPharma shares in Q4 2023, an estimated $428K.
  • Formidable Asset Management first reported a position in Mereo BioPharma in Q2 2022 and held it in 5 quarters.
  • Formidable Asset Management's Mereo BioPharma position peaked at $428K in Q3 2023.
  • 64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2023.

Based on Formidable Asset Management's 13F filing for Q4 2023, filed 7 Feb 2024.